Pedro Bausero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pedro Bausero has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Visioli
Department of Molecular Medicine, University of Padova, Padova, Italy
8 shared publications Ullah Barbe
UPMC Univ Paris 06, CNRS UMR8256/INSERM ERL U1164, Institut de Biologie Paris Seine, Paris, France
6 shared publicationsClaude Wolf
Laboratory of Mass Spectrometry, ERL INSERM U 1057/UMR 7203, Université Pierre et Marie Curie, Paris, France
4 shared publicationsKaouthar Kefi
UPMC Univ Paris 06, CNRS UMR8256/INSERM ERL U1164, Institut de Biologie Paris Seine, Paris, France
4 shared publicationsAntonin Lamaziere
Laboratory of Mass Spectrometry, ERL INSERM U 1057/UMR 7203, Université Pierre et Marie Curie, Paris, France
3 shared publicationsDoriane Richard
UPMC Univ Paris 06, CNRS UMR8256/INSERM ERL U1164, Institut de Biologie Paris Seine, Paris, France
3 shared publications
Latest Publications
- 1 April 2014
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 90 (4) , 139-143
Infusion of docosahexaenoic acid protects against myocardial infarction
- 1 April 2014
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 90 (4) , 139-143
Infusion of docosahexaenoic acid protects against myocardial infarction
- Open Access
- 12 July 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (31) , 12655-12660
CTIP2 is a negative regulator of P-TEFb
The positive transcription elongation factor b (P-TEFb) is involved in physiological and pathological events including inflammation, cancer, AIDS, and cardiac hypertrophy. The balance between its active and inactive form is tightly controlled to ensure cellular integrity. We report that the transcriptional repressor CTIP2 is a major modulator of P-TEFb activity. CTIP2 copurifies and interacts with an inactive P-TEFb complex containing the 7SK snRNA and HEXIM1. CTIP2 associates directly with HEXIM1 and, via the loop 2 of the 7SK snRNA, with P-TEFb. In this nucleoprotein complex, CTIP2 significantly represses the Cdk9 kinase activity of P-TEFb. Accordingly, we show that CTIP2 inhibits large sets of P-TEFb- and 7SK snRNA-sensitive genes. In hearts of hypertrophic cardiomyopathic mice, CTIP2 controls P-TEFb-sensitive pathways involved in the establishment of this pathology. Overexpression of the β-myosin heavy chain protein contributes to the pathological cardiac wall thickening. The inactive P-TEFb complex associates with CTIP2 at the MYH7 gene promoter to repress its activity. Taken together, our results strongly suggest that CTIP2 controls P-TEFb function in physiological and pathological conditions.
- 12 July 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (31) , 12655-12660
Open AccessCTIP2 is a negative regulator of P-TEFb
The positive transcription elongation factor b (P-TEFb) is involved in physiological and pathological events including inflammation, cancer, AIDS, and cardiac hypertrophy. The balance between its active and inactive form is tightly controlled to ensure cellular integrity. We report that the transcriptional repressor CTIP2 is a major modulator of P-TEFb activity. CTIP2 copurifies and interacts with an inactive P-TEFb complex containing the 7SK snRNA and HEXIM1. CTIP2 associates directly with HEXIM1 and, via the loop 2 of the 7SK snRNA, with P-TEFb. In this nucleoprotein complex, CTIP2 significantly represses the Cdk9 kinase activity of P-TEFb. Accordingly, we show that CTIP2 inhibits large sets of P-TEFb- and 7SK snRNA-sensitive genes. In hearts of hypertrophic cardiomyopathic mice, CTIP2 controls P-TEFb-sensitive pathways involved in the establishment of this pathology. Overexpression of the β-myosin heavy chain protein contributes to the pathological cardiac wall thickening. The inactive P-TEFb complex associates with CTIP2 at the MYH7 gene promoter to repress its activity. Taken together, our results strongly suggest that CTIP2 controls P-TEFb function in physiological and pathological conditions.
- 1 February 2013
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 88 (2) , 149-154
Lipidomics of hepatic lipogenesis inhibition by omega 3 fatty acids
- 1 February 2013
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 88 (2) , 149-154
Lipidomics of hepatic lipogenesis inhibition by omega 3 fatty acids
- 1 January 2011
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 84 (1-2) , 7-11
Differential distribution of DHA-phospholipids in rat brain after feeding: A lipidomic approach
- 1 January 2011
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 84 (1-2) , 7-11
Differential distribution of DHA-phospholipids in rat brain after feeding: A lipidomic approach
- 23 August 2010
- Published by Wiley in Muscle & Nerve
- Vol. 42 (4) , 584-595
MMP‐9 overexpression improves myogenic cell migration and engraftment
Myoblast migration requires matrix metalloproteinase (MMP) activity but the contribution of individual MMPs or tissue inhibitors of matrix metalloproteinase (TIMPs), particularly MMP‐9 and TIMP‐1, is lacking. Using two clones derived for differential regulation of MMP‐2, MMP‐9, and TIMP‐1, we correlated protein expression with cell migration. MMP/TIMP regulation was determined by zymography, western blots, and quantitative reverse transcriptase–polymerase chain reaction (qRT‐PCR). Cell migration was compared in vitro and after grafting into nude–mdx mouse muscles. C2M9 clones produced high MMP‐9 and low MMP‐2, and migrated better than C2F clones, which secreted low MMP‐9, but overexpressed MMP‐2 and TIMP‐1. Improvement of C2F invasion by MMP‐9 and inhibition of C2M9 migration by MMP‐9 inhibitor I confirmed the role of MMP‐9 and pointed to potential inhibition by TIMP‐1. Higher complementation achieved by C2M9 grafts corroborated the beneficial effect of MMP‐9 overexpression. Modulation of MMP‐9 expression opens perspectives for improved efficacy of cell therapy for muscular dystrophies. Muscle Nerve, 2010
- 23 August 2010
- Published by Wiley in Muscle & Nerve
- Vol. 42 (4) , 584-595
MMP‐9 overexpression improves myogenic cell migration and engraftment
Myoblast migration requires matrix metalloproteinase (MMP) activity but the contribution of individual MMPs or tissue inhibitors of matrix metalloproteinase (TIMPs), particularly MMP‐9 and TIMP‐1, is lacking. Using two clones derived for differential regulation of MMP‐2, MMP‐9, and TIMP‐1, we correlated protein expression with cell migration. MMP/TIMP regulation was determined by zymography, western blots, and quantitative reverse transcriptase–polymerase chain reaction (qRT‐PCR). Cell migration was compared in vitro and after grafting into nude–mdx mouse muscles. C2M9 clones produced high MMP‐9 and low MMP‐2, and migrated better than C2F clones, which secreted low MMP‐9, but overexpressed MMP‐2 and TIMP‐1. Improvement of C2F invasion by MMP‐9 and inhibition of C2M9 migration by MMP‐9 inhibitor I confirmed the role of MMP‐9 and pointed to potential inhibition by TIMP‐1. Higher complementation achieved by C2M9 grafts corroborated the beneficial effect of MMP‐9 overexpression. Modulation of MMP‐9 expression opens perspectives for improved efficacy of cell therapy for muscular dystrophies. Muscle Nerve, 2010
- 1 November 2009
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 389 (3) , 516-522
Docosahexaenoic acid down-regulates endothelial Nox 4 through a sPLA2 signalling pathway
- 1 November 2009
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 389 (3) , 516-522
Docosahexaenoic acid down-regulates endothelial Nox 4 through a sPLA2 signalling pathway
- Open Access
- 10 July 2009
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 66 (20) , 3277-3288
Polyunsaturated fatty acids and cardiovascular disease
Replacing saturated with polyunsaturated (PUFAs) rather than monounsaturated fatty acids or carbohydrates results in cardiovascular prevention over a wide range of intakes. The mechanisms by which PUFAs reduce cardiovascular risk are manifold, and the extent and precise nature of their activities is the subject of several investigations, spanning from in vitro mechanistic studies to human intervention trials. This article reviews the most up-to-date evidence of the association between PUFA consumption and reduced cardiovascular mortality.
- 10 July 2009
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 66 (20) , 3277-3288
Open AccessPolyunsaturated fatty acids and cardiovascular disease
Replacing saturated with polyunsaturated (PUFAs) rather than monounsaturated fatty acids or carbohydrates results in cardiovascular prevention over a wide range of intakes. The mechanisms by which PUFAs reduce cardiovascular risk are manifold, and the extent and precise nature of their activities is the subject of several investigations, spanning from in vitro mechanistic studies to human intervention trials. This article reviews the most up-to-date evidence of the association between PUFA consumption and reduced cardiovascular mortality.
- Open Access
- 8 May 2009
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (13) , 1648-1655
A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy
Familial hypertrophic cardiomyopathy (FHC) is caused by mutations in genes encoding sarcomeric proteins. Incomplete penetrance suggests the existence of modifier genes. Calmodulin (CaM) could be of importance given the key role of Ca2+ for cardiac contractile function and growth. Any variant that affects CaM expression and/or function may impact on FHC clinical expression. We screened the promoter region of human calmodulin III gene (CALM3) and identified a new −34T>A polymorphism with a T-allele frequency of 0.70. The distribution of CALM3 genotypes differed in 180 unrelated FHC patients carrying a known FHC mutation compared with 134 controls, with higher TT-genotype frequency (0.73 vs. 0.51) and lower frequencies of AT- (0.24 vs. 0.37) and AA genotypes (0.03 vs. 0.11; P = 0.0005). To study whether the −34T>A polymorphism could play a modifier role, patients’ relatives including both affected and healthy carriers were added. Affected carriers had a 0.56 times higher odds of carrying a T allele than healthy carriers (P = 0.053). We then investigated whether the −34T>A polymorphism affects the promoter activity using luciferase reporter vectors containing either CALM3-T or CALM3-A promoters. The activity of CALM3-T was lower than CALM3-A in HEK293 cells (1.00 ± 0.19 vs. 2.31 ± 0.13, P = 0.00001) and in cardiomyocytes (0.96 ± 0.10 vs. 1.33 ± 0.08, P = 0.00727). These data suggest that the −34T>A CALM3 polymorphism is a modifier gene for FHC, potentially by affecting expression level of CALM3 and therefore Ca2+-handling and development of hypertrophy.
- 8 May 2009
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (13) , 1648-1655
Open AccessA new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy
Familial hypertrophic cardiomyopathy (FHC) is caused by mutations in genes encoding sarcomeric proteins. Incomplete penetrance suggests the existence of modifier genes. Calmodulin (CaM) could be of importance given the key role of Ca2+ for cardiac contractile function and growth. Any variant that affects CaM expression and/or function may impact on FHC clinical expression. We screened the promoter region of human calmodulin III gene (CALM3) and identified a new −34T>A polymorphism with a T-allele frequency of 0.70. The distribution of CALM3 genotypes differed in 180 unrelated FHC patients carrying a known FHC mutation compared with 134 controls, with higher TT-genotype frequency (0.73 vs. 0.51) and lower frequencies of AT- (0.24 vs. 0.37) and AA genotypes (0.03 vs. 0.11; P = 0.0005). To study whether the −34T>A polymorphism could play a modifier role, patients’ relatives including both affected and healthy carriers were added. Affected carriers had a 0.56 times higher odds of carrying a T allele than healthy carriers (P = 0.053). We then investigated whether the −34T>A polymorphism affects the promoter activity using luciferase reporter vectors containing either CALM3-T or CALM3-A promoters. The activity of CALM3-T was lower than CALM3-A in HEK293 cells (1.00 ± 0.19 vs. 2.31 ± 0.13, P = 0.00001) and in cardiomyocytes (0.96 ± 0.10 vs. 1.33 ± 0.08, P = 0.00727). These data suggest that the −34T>A CALM3 polymorphism is a modifier gene for FHC, potentially by affecting expression level of CALM3 and therefore Ca2+-handling and development of hypertrophy.